NCT06687070
See how this trial matches your record
Connect MyChart to see which criteria your record clearly satisfies, which need a clinician’s review, and which appear to disqualify you. Your data is read in this browser tab and never sent to our servers.
An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.
Sun Yat-sen University Cancer Center
Guangzhou, China
Jundong Li, M.D. · 020-87343292 · lijd@sysucc.org.cn